[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-455650-105":59,"doc-detail-455650-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrative-analysis-of-at-classification-plasma-biomarkers-and-cognitive-trajectories-across-diverse-dementia-syndromes","Integrative analysis of AT classification, plasma biomarkers, and cognitive trajectories across diverse dementia syndromes","","Study evaluates amyloid-β (Aβ) and tau (AT) biological stages, plasma biomarker profiles, and cognitive trajectories across Alzheimer’s disease-related cognitive impairment (ADCI), subcortical vascular cognitive impairment (SVCI), and frontotemporal dementia (FTD). Among 275 participants, Aβ/tau PET was used to assign AT stages, followed by classification into clinical mild cognitive impairment or dementia. Over 6.1 years, mixed-effects models link distinct biomarker patterns with heterogeneity in cognitive decline across AT categories and dementia types.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrative-analysis-of-at-classification-plasma-biomarkers-and-cognitive-trajectories-across-diverse-dementia-syndromes/455650/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrative-analysis-of-at-classification-plasma-biomarkers-and-cognitive-trajectories-across-diverse-dementia-syndromes/455650.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-08","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study regarding AT classification?","Question",{"text":112,"@type":113},"To examine amyloid-β (Aβ) and tau (AT) biological stages and how they relate to plasma biomarkers and cognitive trajectories across multiple dementia syndromes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were AT stages determined in this research?",{"text":117,"@type":113},"Participants underwent Aβ and tau positron emission tomography (PET), and classification was based on AT staging derived from these imaging assessments.",{"name":119,"@type":110,"acceptedAnswer":120},"What cognitive trajectory differences were observed across dementia groups at the same AT stage?",{"text":121,"@type":113},"SVCI and FTD showed faster cognitive decline than cognitively unimpaired controls at equivalent AT stages, while ADCI showed faster decline than controls mainly in specific AT categories.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},455650,1790790040,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nIntegrative analysis of AT classification, plasma biomarkers, and cognitive trajectories across diverse dementia syndromes  \nJihwan Yun1,25, Min Young Chun2,3,25, Henrik Zetterberg4,5,6,7,8,9, Kaj Blennow4,5,10,11, Fernando Gonzalez-Ortiz4,5, Nicholas J. Ashton4,12,13,14, Daeun Shin15, Soyeon Yoon15, Heejin Yoo15, Jun Pyo Kim15, Hongki Ham15, Yuna Gu15, Hee Jin Kim15,16,17,  \nSeung Hwan Moon18, Hanna Cho19, Jae Yong Choi20, Byung Hyun Byun21, Su Yeon Park22, Jeong Ho Ha22, Duk L. Na23, Sang Won Seo15,16,17􀀍 & Hyemin Jang24􀀍  \nThis study aimed to examine amyloid-β (Aβ) and tau (AT) biological stages, plasma biomarkers, and cognitive trajectories according to AT stages in Alzheimer’s disease-related cognitive impairment (ADCI), subcortical vascular cognitive impairment (SVCI), and frontotemporal dementia (FTD). A total of 275 participants (42 cognitively unimpaired [CU], 132 ADCI, 73 SVCI, and 28 FTD) underwent Aβ and tau positron emission tomography for assessment of AT stages. Participants with cognitive impairment (ADCI, SVCI, and FTD) were classified according to clinical stages of mild cognitive impairment or dementia. Plasma biomarkers were analysed, and cognitive trajectories were assessed using mixedeffects models over 6.1 years. SVCI and FTD showed more advanced clinical stages thanADCI at equivalent AT stages. SVCI participants had higher plasma glial fibrillary acidic protein (P = 0.012) and neurofilament light chain (P = 0.025) than CU participants in theA −T− stage. In theA −T− stage, SVCI (β = -0.738, P = 0.002) and FTD (β = -4.016, P \u003C 0.001) showed faster cognitive decline than CU, but not ADCI. In theA +T − stage, ADCI (β = -0.634, P = 0.005) and SVCI (β = -0.690, P = 0.006) showed faster decline than CU. In theA +T + stage, only ADCI exhibited significantly faster decline than CU (β = -1.856, P = 0.008). Distinct plasma biomarker profiles and cognitive trajectories characterise ADCI, SVCI, and FTD across AT classification, highlighting the heterogeneity in pathophysiological mechanisms across dementia types.  \nKeywords Amyloid-β, Tau, Alzheimer’s disease, Subcortical vascular cognitive impairment, Frontotemporal dementia, Positron emission tomography  \nAbbreviations  \nCU  \nADCI  \nSVCI  \nFTD  \nA  \nT  \nMCI  \nSUVR  \nSVCI  \nFTD  \nROI  \np-tau217 GFAP  \nNfL  \nMMSE  \nPET  \nCognitively unimpaired  \nAlzheimer’s disease-type cognitive impairment Subcortical vascular cognitive impairment Frontotemporal dementia  \nAmyloid Tau  \nMild cognitive impairment Standardized uptake value ratio Subcortical vascular cognitive impairment Frontotemporal dementia  \nRegion of interest Phosphorylated-tau217  \nGlial fibrillary acidic protein Neurofilament light chain Mini-mental state examination Positron emission tomography  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \n1Department of Neurology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, South Korea. 2Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea. 3Department of Neurology, Yongin Severance Hospital, Yonsei University Health System, Yongin, South Korea. 4Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. 5Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden. 6Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK. 7UK Dementia Research Institute at UCL, London, UK. 8Hong Kong Center for Neurodegenerative Diseases, InnoHK, Clear Water Bay, Hong Kong, China. 9Wisconsin Alzheimer’s Disease Research Center, School of Medicine and Public Health, University of Wisconsin, University of Wisconsin-Madison, Madison, WI 53792, USA. 10Pitié-Salpêtrière Hospital, Paris Brain Institute, ICM, Sorbonne University, Paris, France.  \n11Neurodeg","cbCaivD3zrIDm9II","https://ap.wps.com/l/cbCaivD3zrIDm9II","pdf",4090634,13,"English","# Study aims and design\n# Participant classification and AT staging\n# Plasma biomarker analysis\n# Cognitive trajectories over follow-up\n# Key group comparisons and findings","[{\"question\":\"What is the main goal of the study regarding AT classification?\",\"answer\":\"To examine amyloid-β (Aβ) and tau (AT) biological stages and how they relate to plasma biomarkers and cognitive trajectories across multiple dementia syndromes.\"},{\"question\":\"How were AT stages determined in this research?\",\"answer\":\"Participants underwent Aβ and tau positron emission tomography (PET), and classification was based on AT staging derived from these imaging assessments.\"},{\"question\":\"What cognitive trajectory differences were observed across dementia groups at the same AT stage?\",\"answer\":\"SVCI and FTD showed faster cognitive decline than cognitively unimpaired controls at equivalent AT stages, while ADCI showed faster decline than controls mainly in specific AT categories.\"}]","Integrative analysis of AT classification, plasma biomarkers, and cognitive trajectories across diverse dementia syndromes | PDF",1790743756,33]